Journey Medical Corporation (DERM)
Largest Insider Buys in Sector
DERM Stock Price History Chart
DERM Stock Performance
About Journey Medical Corporation
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Insider Activity of Journey Medical Corporation
Over the last 12 months, insiders at Journey Medical Corporation have bought $237,290 and sold $82,087 worth of Journey Medical Corporation stock.
On average, over the past 5 years, insiders at Journey Medical Corporation have bought $256.04M and sold $77,042 worth of stock each year.
Highest buying activity among insiders over the last 12 months: ROSENWALD LINDSAY A MD (director) — $688,800. Smith Justin Adam (director) — $104,100. Maraoui Claude (President & CEO) — $34,790.
The last purchase of 10,000 shares for transaction amount of $30,400 was made by ROSENWALD LINDSAY A MD (director) on 2024‑03‑25.
List of Insider Buy and Sell Transactions, Journey Medical Corporation
| 2024-08-01 | Sale | CFO | 9,324 0.0422% | $5.47 | $51,002 | -5.97% | ||
| 2024-07-23 | Sale | CFO | 4,055 0.0181% | $5.40 | $21,897 | -3.33% | ||
| 2024-03-25 | director | 10,000 0.0252% | $3.04 | $30,400 | +74.32% | |||
| 2024-03-22 | President & CEO | 10,000 0.0288% | $3.48 | $34,790 | +54.09% | |||
| 2024-03-22 | director | 30,000 0.0862% | $3.47 | $104,100 | +54.09% | |||
| 2024-03-22 | director | 20,000 0.0563% | $3.40 | $68,000 | +54.09% | |||
| 2024-02-22 | Sale | Interim CFO | 2,450 0.0076% | $3.75 | $9,188 | +32.80% | ||
| 2023-11-28 | Sale | director | 1,745 0.0075% | $5.22 | $9,109 | -7.50% | ||
| 2023-11-08 | Sale | director | 255 0.0008% | $3.76 | $959 | +31.78% | ||
| 2023-11-07 | Sale | director | 2,245 0.0065% | $3.48 | $7,813 | +44.02% | ||
| 2023-10-13 | director | 33,000 0.0814% | $2.98 | $98,340 | +57.19% | |||
| 2023-10-06 | director | 15,000 0.037% | $2.98 | $44,700 | +58.13% | |||
| 2023-09-21 | director | 30,000 0.0738% | $2.97 | $89,100 | +48.15% | |||
| 2023-09-06 | President & CEO | 26,044 0.0544% | $2.52 | $65,631 | +70.32% | |||
| 2023-09-06 | director | 100,000 0.1847% | $2.23 | $223,000 | +70.32% | |||
| 2023-07-24 | Sale | President & CEO | 20,767 0.0303% | $1.76 | $36,550 | +108.06% | ||
| 2023-07-24 | Sale | See Remarks | 4,072 0.0059% | $1.76 | $7,167 | +108.06% | ||
| 2023-05-17 | Sale | President & CEO | 24,377 0.0271% | $1.34 | $32,665 | +175.40% | ||
| 2023-05-16 | Sale | President & CEO | 20,000 0.0207% | $1.25 | $25,000 | +127.00% | ||
| 2023-02-22 | Sale | Interim CFO | 2,768 0.0045% | $1.97 | $5,453 | +16.06% |
Insider Historical Profitability
| Maraoui Claude | President & CEO | 2163430 10.3563% | $3.84 | 2 | 3 | +70.32% |
| ROSENWALD LINDSAY A MD | director | 144245 0.6905% | $3.84 | 3 | 0 | +70.32% |
| Smith Justin Adam | director | 134717 0.6449% | $3.84 | 2 | 0 | +57.19% |
| Benesch Joseph | CFO | 47331 0.2266% | $3.84 | 0 | 5 | |
| BARRIS PETER J | 10 percent owner | 3502922 16.7685% | $3.84 | 1 | 0 | |
| MOTT DAVID M | 10 percent owner | 3502922 16.7685% | $3.84 | 1 | 0 | |
| KERINS PATRICK J | 10 percent owner | 3502922 16.7685% | $3.84 | 1 | 0 | |
| SANDELL SCOTT D | 10 percent owner | 3502922 16.7685% | $3.84 | 1 | 0 | |
| KOLLURI KRISHNA KITTU | 10 percent owner | 3502922 16.7685% | $3.84 | 1 | 0 | |
| DRANT RYAN D | 10 percent owner | 3502922 16.7685% | $3.84 | 1 | 0 | |
| NEW ENTERPRISE ASSOCIATES 13 LP | 10 percent owner | 3502922 16.7685% | $3.84 | 1 | 0 | |
| Viswanathan Ravi | 10 percent owner | 3502922 16.7685% | $3.84 | 1 | 0 | |
| Canaan VIII LP | 2500149 11.9682% | $3.84 | 1 | 0 | ||
| De Paolantonio Ernest Robert | See Remarks | 259907 1.2442% | $3.84 | 0 | 1 | |
| Paley Jeffrey | director | 70727 0.3386% | $3.84 | 2 | 3 | +53.14% |
| CRAVES FRED B | 30000 0.1436% | $3.84 | 3 | 0 | ||
| Cohen David E | director | 29682 0.1421% | $3.84 | 0 | 8 | |
| BAUER EUGENE A | Chief Medical Officer | 8900 0.0426% | $3.84 | 0 | 28 | |
| GUGGENHIME ANDREW | COO and CFO | 5116 0.0245% | $3.84 | 0 | 6 | |
| Fust Matthew K | director | 5051 0.0242% | $3.84 | 1 | 4 | |
| RINGO WILLIAM R | director | 0 0% | $3.84 | 0 | 11 |